Selected article for: "animal model and low number"
Author: Papaneri, Amy B.; Johnson, Reed F.; Wada, Jiro; Bollinger, Laura; Jahrling, Peter B.; Kuhn, Jens H.
Title: Middle East respiratory syndrome: obstacles and prospects for vaccine development
  • Cord-id: bytd4ueh
  • Document date: 2015_4_11
    • ID: bytd4ueh
    Snippet: The recent emergence of Middle East respiratory syndrome (MERS) highlights the need to engineer new methods for expediting vaccine development against emerging diseases. However, several obstacles prevent pursuit of a licensable MERS vaccine. First, the lack of a suitable animal model for MERS complicates in vivo testing of candidate vaccines. Second, due to the low number of MERS cases, pharmaceutical companies have little incentive to pursue MERS vaccine production as the costs of clinical tri
    Document: The recent emergence of Middle East respiratory syndrome (MERS) highlights the need to engineer new methods for expediting vaccine development against emerging diseases. However, several obstacles prevent pursuit of a licensable MERS vaccine. First, the lack of a suitable animal model for MERS complicates in vivo testing of candidate vaccines. Second, due to the low number of MERS cases, pharmaceutical companies have little incentive to pursue MERS vaccine production as the costs of clinical trials are high. In addition, the timeline from bench research to approved vaccine use is 10 years or longer. Using novel methods and cost-saving strategies, genetically engineered vaccines can be produced quickly and cost-effectively. Along with progress in MERS animal model development, these obstacles can be circumvented or at least mitigated.

    Search related documents:
    Co phrase search for related documents
    • accessory structural and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • accessory structural and adaptive immune response: 1
    • actual number and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5
    • actual number and additional cost: 1
    • acute sars cov respiratory syndrome coronavirus and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars cov respiratory syndrome coronavirus and additional cost: 1, 2, 3, 4, 5
    • acute sars cov respiratory syndrome coronavirus and adenovirus vaccine platform: 1
    • acute sars cov respiratory syndrome coronavirus and administration adjuvant: 1, 2, 3